

Boehringer Ingelingim KG - 6507 Ingelingim am Rhain

Boehringer Ingelheim KG

Prof. Dr. P. Placheta Bender & Co. Ges.m.b.H. Dr.-Boehringer-Gasse 5 - 11 A-1120 Wien

ar Zeichen

live Nactricht vom Unser Zeichen

Tololon-Durchwishl Dr. Mū-ra

6507 Ingenem am Rhein

05132-77-4194

denNovember 8., 1989

Dear Prof. Placheta,

we have given serious consideration to the proposal of Waldheim Pharmazeutika to develop Nivalin (galanthamine) for the indication Alzheimer's disease. Based on the extensive preclinical research data available to us, it is our feeling that this compound, while interesting from the point of view of its mechanism of action (acetylcholinesterase inhibitor), does not have the biochemical and pharmacological profile which we consider essential for its potential use in the treatment of Alzheimer's disease. The limited clinical data (pilot study by Michael Rainer) are not very convincing.

Furthermore, Dr. Bonnie Davis has already applied for a patent to use galanthamine in AD-patients in the US and several other countries. To my knowledge, this patent has been granted and Waldheim Pharmazeutika is well aware of this.

We would, therefore, not recommend that Boehringer should get involved in the development of Nivalin for the treatment of Alzheimer's disease.

With best regards

BOEHRINGER INGELHEIM KG

ppa.

Dr. M. Herschel

(Dept. of Medicine)

of. E. Müller

(Dept. of Pharmacology)

. cc.: Prof. Jennewein

Dr. Bachtler

Dr. Heil

Dr. Bonnie Davis

(Mount Sinai Medical Center, N.Y.)